Ningetinib Tosylate is a small-molecule multi-kinase inhibitor primarily used in oncology as a targeted therapy for advanced solid tumors, including non-small cell lung cancer (NSCLC). It selectively inhibits c-Met (hepatocyte growth factor receptor), VEGFR2, FLT3, and other kinases involved in tumor cell proliferation, survival, angiogenesis, and metastasis. This compound is particularly effective in cancers with c-Met amplification, overexpression, or mutation, which are common in NSCLC and other malignancies. By blocking these pathways, it helps to slow or halt disease progression. Ongoing research explores its potential in combination therapies and for other c-Met-driven cancers, such as gastric and liver cancers. Treatment is often guided by tumor genetic profiling to optimize efficacy and reduce side effects.